Key facts
- It has raised $16.3M; the latest was Later Stage VC in Jan 2026.
- Notable investors include Dalton Venture, Shenzhen CDF Capital, Chengdu Bio-Town Investment, Chengdu Venture Capital, Daoyuan Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Yanyang Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Yanyang Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yanyang Biotech
Operator of a biotechnology company focusing on the R&D of innovative microbial drugs. The company applies its core technology to the screening of anaerobic microorganisms, bacterial drug evaluation and storage and transportation of live bacteria, and its self-developed "KAL-001" series of live multi-linkage bacteria drugs have entered the stage of clinical trials.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2019
- Employees
- 9
- Website
- scyysw.cn/
- Ownership
- Privately Held (backing)
Yanyang Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yanyang Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yanyang Biotech in its N-PORT filings yet. We sweep new filings monthly.